Table 2.
Hazard ratios (HR) for Overall survival (OS) and Progression-free survival (PFS). PFS and OS and corresponding 95%CI and p-values. Univariate Model
| OS | PFS | ||||
|---|---|---|---|---|---|
| Clinicopathologic characteristics | HR (95%CI) | p | HR (95%CI) | p | |
| Age – years | ≤ 70 vs > 70 | 1.36 (0.92–2.01) | 0,12 | 1.07 (0.75–1.52) | 0,72 |
| <60 | 1 | 1 | – | ||
| 60– 65 | 0.69 (0.37–1.25) | 0,22 | 0.81 (0.48–1.36) | 0,42 | |
| 65– 70 | 0.75 (0.46–1.22) | 0,25 | 1.02 (0.67–1.55) | 0,94 | |
| 70– 75 | 1.22 (0.70–2.14) | 0,48 | 1.25 (0.76–2.07) | 0,38 | |
| 75 | 0.96 (0.56–1.65) | 0,87 | 0.85 (0.53–1.38) | 0,52 | |
| Sex | Female | 1 | 1 | – | |
| Male | 1.00 (0.67–1.49) | 0,99 | 1.10 (0.78–1.55) | 0,60 | |
| BMI – kg/m2 | <25 | 1 | 1 | ||
| ≤ 25 | 0.68 (0.47–0.99) | 0,04 | 0.96 (0.70–1.33) | 0,81 | |
| Smoking status | No | 1 | 1 | – | |
| Yes | 1.19 (0.60–2.35) | 0,63 | 0.82 (0.46–1.46) | 0,49 | |
| ECOG – OMS | 0 vs ≥ 1 | 2.26 (1.49–3.42) | <0.001 | 1.58 (1.11–2.24) | <0,001 |
| Histology | ADK | 1 | 1 | – | |
| EPI | 1.15 (0.79–1.69) | 0,46 | 1.08 (0.77–1.52) | 0,66 | |
| Tumor stage | LA | 1 | 1 | – | |
| META | 1.47 (0.68–3.15) | 0,32 | 1.05 (0.58–1.91) | 0,87 | |
| Brain metastases | No | – | |||
| Yes | 1.11 (0.74–1.66) | 0,62 | 1.10 (0.77–1.57) | 0,60 | |
| EGFR mutation | No | – | |||
| Yes | 1.06 (0.57–1.94) | 0,86 | 0.90 (0.51–1.57) | 0,70 | |
| Treatment line | 1 | 1 | 1 | – | |
| ≥ 2 | 1.40 (0.70–2.77) | 0,34 | 1.76 (1.05–2.96) | 0,03 | |
| Co-medication | Corticosteroids | 1.46 (0.97–2.21) | 0,07 | 1.12 (0.76–1.65) | 0,56 |
| Metformin | 1.07 (0.54–2.11) | 0,86 | 1.37 (0.77–2.43) | 0,29 | |
| Statin | 1.33 (0.89–2.00) | 0,16 | 1.14 (0.79–1.65) | 0,50 | |
| Beta-blocker | 1.27 (0.83–1.95) | 0,27 | 1.17 (0.80–1.73) | 0,42 | |
| ACE inhibitors | 1.61 (0.96–2.69) | 0,07 | 1.79 (1.13–2.83) | 0,01 | |
| ARA2 | 1.00 (0.60–1.65) | 0,99 | 0.84 (0.53–1.33) | 0,46 | |
| ATB | 0.63 (0.38–1.06) | 0,08 | 0.66 (0.43–1.02) | 0,06 | |
Hazard ratios (HR) and 95% confidence interval (CI) were estimated from univariate Cox Proportion Hazard model.
Wald test was used to test if each HR was statistically significantly different from 1.
ACE: angiotensin-converting-enzyme. ARA2: angiotensin II receptor antagonists. ATB: antibiotics. BMI: body mass index. ADK: adenocarcinoma. EPI: squamous cell. LA: locally advanced. META: metastatic